New Dual GLP-1/GIP Drug Ribupatide Shows Promise for Weight Loss in Pill and Shot Form
Hengrui and Kailera will share Phase 1 and 2 clinical data on ribupatide, a dual GLP-1/GIP agonist, at ADA 2025 in June.
Summary
Ribupatide is a new weight-loss drug that targets two hormone receptors — GLP-1 and GIP — the same pathways used by popular obesity medications like tirzepatide. Developed by Hengrui Pharma and Kailera Therapeutics, it is being tested in both a once-weekly injection and a once-daily pill. Clinical trial results will be presented at the American Diabetes Association's Scientific Sessions in June 2026. Phase 2 data covers the oral version in adults with obesity, while Phase 1 bridging data helped launch a global Phase 3 trial program called KaiNETIC. If successful, ribupatide could offer more flexible treatment options for people managing obesity, with both injectable and oral formats aimed at strong weight loss outcomes and improved tolerability.
Detailed Summary
Obesity treatment is entering a new competitive era, and ribupatide is one of the most closely watched entrants. Developed jointly by Chinese pharma company Hengrui and US-based Kailera Therapeutics, ribupatide is a dual agonist targeting both GLP-1 and GIP receptors — the same hormonal pathways activated by tirzepatide (Mounjaro/Zepbound), currently one of the most effective weight-loss drugs available. The key differentiator here is format flexibility: ribupatide is being advanced as both a once-weekly subcutaneous injection and a once-daily oral tablet.
At the American Diabetes Association's 86th Scientific Sessions in New Orleans (June 5–8, 2026), two separate abstracts will be presented. Hengrui will share Phase 2 results for the oral formulation in adults living with obesity, while Kailera will present Phase 1 bridging data for its injectable candidate, KAI-9531. Both presentations are poster sessions on June 7 and 8 respectively.
The Phase 1 bridging study was a randomized, double-blind, single-ascending dose design — a standard early-stage approach to assess safety, tolerability, and pharmacokinetics. Kailera states this data was sufficient to support the launch of its global Phase 3 program, KaiNETIC, which is currently ongoing. Phase 3 trials are the final hurdle before regulatory approval and will determine whether ribupatide is safe and effective at scale.
For health-conscious individuals and clinicians, the significance lies in the potential for an effective oral GLP-1/GIP option. Current leading dual agonists are injectable only, which limits adherence for some patients. A daily pill with comparable efficacy could dramatically expand access and convenience.
Caveats are significant: this article is a conference announcement, not a results release. Actual efficacy and safety data have not yet been made public. The full Phase 2 and Phase 3 outcomes will be critical before drawing conclusions about ribupatide's place in obesity treatment.
Key Findings
- Ribupatide targets both GLP-1 and GIP receptors, the same dual pathway as tirzepatide, one of the most effective obesity drugs.
- Both a once-weekly injectable and once-daily oral pill formats are in active clinical development.
- Phase 2 oral ribupatide data in adults with obesity will be publicly presented for the first time in June 2026.
- Phase 1 bridging data for injectable KAI-9531 was strong enough to initiate a global Phase 3 trial program.
- An effective oral GLP-1/GIP agonist could improve treatment adherence and expand access for people with obesity.
Methodology
This is a news report summarizing a conference presentation announcement, not a peer-reviewed study. Source is Longevity.Technology, a credible health-tech publication. No clinical data has been released yet; findings will be presented at ADA 2026 and published in the journal Diabetes.
Study Limitations
No actual clinical results have been published or disclosed in this article — only that presentations are forthcoming. Phase 3 outcomes are still pending, and regulatory approval is years away. Independent verification of efficacy and safety data should be sought from primary published abstracts in the journal Diabetes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.